SATO VICKI L 4
4 · Vir Biotechnology, Inc. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
Vir Biotechnology (VIR) Director Vicki L. Sato Sells 22,000 Shares
What Happened
Vicki L. Sato, a director of Vir Biotechnology (VIR), sold a total of 22,000 shares on March 2, 2026 in open-market transactions for aggregate proceeds of about $209,181. The filing reports two sale groupings: 21,800 shares (reported weighted average $9.50; proceeds $207,185) and 200 shares (reported weighted average $9.98; proceeds $1,996). All sales are reported as dispositions (code S).
Key Details
- Transaction date: March 2, 2026; Form 4 filed March 3, 2026 (timely filing).
- Sale breakdown:
- 21,800 shares, reported weighted avg price $9.50, proceeds $207,185; per-footnote prices ranged from $8.97 to $9.91.
- 200 shares, reported weighted avg price $9.98, proceeds $1,996; per-footnote prices ranged from $9.97 to $9.99.
- Total sold: 22,000 shares for approximately $209,181.
- Footnote: Sales were effected under a Rule 10b5-1 trading plan adopted March 27, 2025. Reporting person will provide per-price breakdowns on request (per filing footnotes).
- Shares owned after transaction: not specified in the details provided.
- Transaction code: S = Sale (open market/private sale).
Context
A Rule 10b5-1 plan indicates these sales were pre-arranged under an automated trading plan adopted previously (March 27, 2025) and are often used to execute routine dispositions rather than signal a change in insider view; the filing itself is factual and does not state motivations. Retail investors should view routine director sales differently from purchases, which can sometimes be a clearer signal of insider confidence.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-02$9.50/sh−21,800$207,185→ 1,122,591 total - Sale
Common Stock
[F1][F3]2026-03-02$9.98/sh−200$1,996→ 1,122,391 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.97 to $9.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.97 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.